Search
Ceftiofur
go.drugbank.com/drugs/DB11485ExperimentalVet approvedCeftiofur is a third generation cephalosporin antibiotic, first described in 1987, and now used in veterinary medicine. … It is marketed by pharmaceutical company Zoetis as Excenel, and is the active ingredient in that company's Specramast LC (lactating cow formula) product.
Interferon Gamma
go.drugbank.com/drugs/DB15753InvestigationalInterferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions.
ANA971
go.drugbank.com/drugs/DB05127ExperimentalANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection. … ANA971 is a prodrug designed to improve the oral bioavailability of isatoribine.
Zidesamtinib
go.drugbank.com/drugs/DB21623ApprovedInvestigationalanother ROS1 inhibitor has failed rather than as an alternative first choice. … Zidesamtinib is an orally administered ROS1 kinase inhibitor designed to remain active against ROS1 resistance mutations.
EDP1815
go.drugbank.com/drugs/DB16486Investigationalinvestigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions such as
COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection
go.drugbank.com/drugs/DB16520ExperimentalPresentation Therapeutic Biologics (COVID-19--AP) (AP-TP-Bio))[L31333]. … COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection is an intradermal injection currently being investigated in the clinical trial NCT03348670 (Discovery Stage (Proof-of-concept) COVID-19 Antigen
Synonyms: COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection, COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's InjectionDG041
go.drugbank.com/drugs/DB05027ExperimentalDG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. … EP3 is a target that associates with increased risk of various vascular diseases.
Amobarbital
go.drugbank.com/drugs/DB01351ApprovedIllicitA barbiturate with hypnotic and sedative properties (but not antianxiety). … Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)
Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigationalThe reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910] … [A261165] However, challenges in using [tetrabenazine] as a treatment of tardive dyskinesia included frequent dosing and safety and tolerability concerns.